We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 03, 2022

Effects of 26-Week Treatment With Empagliflozin vs Glimepiride on the Myocardial Glucose Metabolic Rate in Patients With Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Effects of 26-week treatment with empagliflozin versus glimepiride on myocardial glucose metabolic rate in patients with type 2 diabetes: the randomized, open-label, active-controlled crossover FIORE trial
Diabetes Obes Metab 2022 Jul 15;[EPub Ahead of Print], E Succurro, P Vizza, A Papa, S Miceli, F Cicone, TV Fiorentino, A Sciacqua, F Andreozzi, P Veltri, GL Cascini, G Sesti

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading